Preventing RSV in the Most Vulnerable PopulationByJohn ParkinsonAugust 10th 2023A clinician offers a glimpse of what it is like to treat infants with respiratory syncytial virus (RSV). And with the recent FDA approval of nirsevimab, how that will likely benefit families and the youngest population.